These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 34841542)

  • 41. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
    Kelly KJ; Alsayadnasser M; Vaida F; Veerapong J; Baumgartner JM; Patel S; Ahmad S; Barone R; Lowy AM
    Ann Surg Oncol; 2019 May; 26(5):1421-1427. PubMed ID: 30815802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad].
    Petursdottir A; Gunnarsson O; Valsdottir EB
    Laeknabladid; 2020 Jul; 106(7):344-348. PubMed ID: 32608356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.
    Ward EP; Okamuro L; Khan S; Hosseini M; Valasek MA; Ronquillo N; Kelly KJ; Veerapong J; Lowy AM; Baumgartner J
    Hum Pathol; 2021 Jul; 113():104-110. PubMed ID: 33905776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
    Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis.
    Munoz-Zuluaga CA; King MC; Diaz-Sarmiento VS; Studeman K; Sittig M; MacDonald R; Nieroda C; Zambrano-Vera K; Gushchin V; Sardi A
    Ann Surg Oncol; 2020 Dec; 27(13):5026-5036. PubMed ID: 32705513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries.
    Votanopoulos KI; Bartlett D; Moran B; Haroon CM; Russell G; Pingpank JF; Ramalingam L; Kandiah C; Chouliaras K; Shen P; Levine EA
    Ann Surg Oncol; 2018 Mar; 25(3):674-678. PubMed ID: 29288288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
    BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
    Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histologic and Immunohistochemical Alterations Associated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy.
    Wagner P; Boone B; Ramalingam L; Jones H; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh H; Choudry H; Bartlett D
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S588-95. PubMed ID: 25948159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 56. Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease?
    Beal EW; Chen JC; Kim A; Johnston FM; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Clarke C; Staley C; Patel SH; Lambert L; Cloyd JM
    J Surg Res; 2022 Sep; 277():269-278. PubMed ID: 35525209
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC; Tan GH; Tham CK; Lim C; Soo KC
    Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection.
    Enomoto LM; Choudry MH; Bartlett DL; Totin L; Mann GN; Skitzki JJ; Perry KC; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2020 Jan; 27(1):107-114. PubMed ID: 31368017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selection and Characteristics of Patients with Peritoneal Dissemination from Appendiceal Cancer with Exceptional/Poor Survival After CRS/HIPEC.
    Munoz-Zuluaga C; King MC; Sardi A; Ledakis P; Sittig M; Nieroda C; MacDonald R; Gushchin V
    Ann Surg Oncol; 2019 Jul; 26(7):2268-2275. PubMed ID: 31041628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.